CIK 0000818033
- Accelerated filer
HERON THERAPEUTICS, INC. /DE/
Sign in to watch- Ticker
- HRTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 942875566
- Phone
- +1 858-251-4400
- Business address
- 4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO, CA, 92121
- Former names
- AP PHARMA INC /DE/, ADVANCED POLYMER SYSTEMS INC /DE/
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2011-04-24 | TANG KEVIN C Director | Grant or award · Rights to Purchase Senior Secured Convertible Notes due 2021 | +0 | |||
| 2011-04-24 | Baker Bros. Capital (GP), LLC 10% owner | Purchase · Senior Secured Convertible Notes due 2021 | +300 | $300.00 | $90K | 300 |
| 2011-04-24 | Baker Bros. Capital (GP), LLC 10% owner | Purchase · Rights to Purchase Senior Secured Convertible Notes due 2021 | +600 | 600 | ||
| 2011-04-24 | 14159 capital (GP), LLC 10% owner | Purchase · Senior Secured Convertible Notes due 2021 | +5,400 | $5,400.00 | $29.2M | 5,400 |
| 2011-04-24 | 14159 capital (GP), LLC 10% owner | Purchase · Rights to Purchase Senior Secured Convertible Notes due 2021 | +10,800 | 10,800 | ||
| 2011-04-24 | Baker Brothers Life Sciences Capital (GP), LLC 10% owner | Purchase · Senior Secured Convertible Notes due 2021 | +294,300 | $294,300.00 | $86.6B | 294,300 |
| 2011-04-24 | Baker Brothers Life Sciences Capital (GP), LLC 10% owner | Purchase · Rights to Purchase Senior Secured Convertible Notes due 2021 | +588,600 | 588,600 | ||
| 2011-02-16 | DAVIS STEPHEN Director | Other disposition | −31,088 | 95,891 | ||
| 2010-07-08 | BARR JOHN Vice President of R&D | Grant or award · Incentive Stock Option (right to buy) | +103,564 | 103,564 | ||
| 2010-07-08 | BARR JOHN Vice President of R&D | Grant or award · Non-Qualified Stock Option (right to buy) | +46,436 | 46,436 | ||
| 2010-07-08 | Whelan John CFO | Grant or award · Incentive Stock Option (right to buy) | +53,092 | 53,092 | ||
| 2010-07-08 | Whelan John CFO | Grant or award · Non-Qualified Stock Option (right to buy) | +96,908 | 96,908 | ||
| 2010-05-20 | TANG KEVIN C Director | Grant or award | +95,891 | 138,841 | ||
| 2010-05-20 | GODDARD PAUL Director | Grant or award | +95,891 | 214,683 | ||
| 2010-05-20 | ZERBE ROBERT L MD Director | Grant or award | +95,891 | 202,072 | ||
| 2010-05-20 | TURNBULL GREG Director | Grant or award | +95,891 | 245,092 | ||
| 2010-05-20 | ROSENBLATT TOBY Director | Grant or award | +95,891 | 210,234 | ||
| 2010-05-20 | DAVIS STEPHEN Director | Grant or award | +5,983 | 37,071 | ||
| 2010-05-20 | DAVIS STEPHEN Director | Grant or award | +89,908 | 126,979 | ||
| 2010-02-17 | DAVIS STEPHEN Director | Grant or award | +31,088 | 31,088 |
Page 42 of 45 · 881 trades